Compare WEAV & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | PRTC |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 400.2M |
| IPO Year | 2021 | N/A |
| Metric | WEAV | PRTC |
|---|---|---|
| Price | $5.41 | $17.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 3.5K |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $239,024,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $14.50 |
| 52 Week High | $11.32 | $19.92 |
| Indicator | WEAV | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 61.15 |
| Support Level | $5.37 | $16.60 |
| Resistance Level | $5.70 | $18.12 |
| Average True Range (ATR) | 0.25 | 0.49 |
| MACD | 0.10 | 0.25 |
| Stochastic Oscillator | 76.68 | 82.30 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.